Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Advanced Small Intestine Adenocarcinoma
NCT03000179Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Mar 2017
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in small intestine adenocarcinoma (SBA), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Overall Response Rate and Number of Patients With Each Worst-Grade Toxicity. Started Mar 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
small intestine adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT03000179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000179.